MedTrace Logo

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

NCT06939036 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-02-05

No results posted yet for this study

Summary

This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Conditions

Interventions

DRUG

225Ac-SSO110 + SoC

Dose Level -2-7

DRUG

Atezolizumab

Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)

DRUG

Durvalumab

Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)

DRUG

Avelumab

Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)

DRUG

Pembrolizumab

Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)

DRUG

Retifanlimab

Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)

Sponsors & Collaborators

  • Ariceum Therapeutics GmbH

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06939036 on ClinicalTrials.gov